167 related articles for article (PubMed ID: 35200148)
1. Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.
Hibler EA; Fought AJ; Kershaw KN; Molsberry R; Nowakowski V; Lindner D
J Med Internet Res; 2022 Feb; 24(2):e29124. PubMed ID: 35200148
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
Ozanne EM; Howe R; Mallinson D; Esserman L; Van't Veer LJ; Kaplan CP
J Genet Couns; 2019 Jun; 28(3):507-515. PubMed ID: 30663827
[TBL] [Abstract][Full Text] [Related]
3. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
[TBL] [Abstract][Full Text] [Related]
4. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
5. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
Daly MB; Pilarski R; Axilbund JE; Berry M; Buys SS; Crawford B; Farmer M; Friedman S; Garber JE; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Marcom PK; Merajver SD; Offit K; Pal T; Rana H; Reiser G; Robson ME; Shannon KM; Swisher E; Voian NC; Weitzel JN; Whelan A; Wick MJ; Wiesner GL; Dwyer M; Kumar R; Darlow S
J Natl Compr Canc Netw; 2016 Feb; 14(2):153-62. PubMed ID: 26850485
[TBL] [Abstract][Full Text] [Related]
6. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.
Levy DE; Garber JE; Shields AE
J Gen Intern Med; 2009 Jul; 24(7):822-8. PubMed ID: 19455369
[TBL] [Abstract][Full Text] [Related]
8. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
Febbraro T; Robison K; Wilbur JS; Laprise J; Bregar A; Lopes V; Legare R; Stuckey A
Gynecol Oncol; 2015 Jul; 138(1):109-14. PubMed ID: 25933682
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer.
Haneda E; Sato A; Suganuma N; Sebata Y; Okamoto S; Toda S; Kohagura K; Matsubara Y; Sugawara Y; Yamanaka T; Yamashita T; Shimizu S; Narimatsu H
Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627717
[TBL] [Abstract][Full Text] [Related]
10. Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool.
Rupert DJ; Squiers LB; Renaud JM; Whitehead NS; Osborn RJ; Furberg RD; Squire CM; Tzeng JP
Patient Educ Couns; 2013 Aug; 92(2):188-96. PubMed ID: 23664232
[TBL] [Abstract][Full Text] [Related]
11. Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina.
Shelton CH; Bowen C; Guenther WC; Jordan B; Boehmer LM; Weldon CB; Trosman JR; Ruiz A
N C Med J; 2022; 83(3):221-228. PubMed ID: 35504701
[No Abstract] [Full Text] [Related]
12. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB; Pal T; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Goggins M; Hutton ML; ; Karlan BY; Khan S; Klein C; Kohlmann W; ; Kurian AW; Laronga C; Litton JK; Mak JS; ; Menendez CS; Merajver SD; Norquist BS; Offit K; Pederson HJ; Reiser G; ; Senter-Jamieson L; ; Shannon KM; Shatsky R; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Yurgelun MB; Darlow SD; Dwyer MA
J Natl Compr Canc Netw; 2021 Jan; 19(1):77-102. PubMed ID: 33406487
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Nelson HD; Huffman LH; Fu R; Harris EL;
Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
15. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
[TBL] [Abstract][Full Text] [Related]
16. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
Kotnik U; Peterlin B; Lovrecic L
BMC Cancer; 2021 Jun; 21(1):665. PubMed ID: 34082720
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian.
Daly MB
Can J Urol; 2019 Oct; 26(5 Suppl 2):29-30. PubMed ID: 31629424
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
19. Impact of Implementing B-RST
Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
